Musculoskeletal and prostate effects of combined testosterone and finasteride administration in older hypogonadal men: a randomized, controlled trial.

Testosterone acts directly at androgen receptors and also exerts potent actions following 5α-reduction to dihydrotestosterone (DHT). Finasteride (type II 5α-reductase inhibitor) lowers DHT and is used to treat benign prostatic hyperplasia. However, it is unknown whether elevated DHT mediates either beneficial musculoskeletal effects or prostate enlargement resulting from higher-than-replacement doses of testosterone. Our purpose was to determine whether administration of testosterone plus finasteride to older hypogonadal men could produce musculoskeletal benefits without prostate enlargement. Sixty men aged ≥60 yr with a serum testosterone concentration of ≤300 ng/dl or bioavailable testosterone ≤70 ng/dl received 52 wk of treatment with testosterone enanthate (TE; 125 mg/wk) vs. vehicle, paired with finasteride (5 mg/day) vs. placebo using a 2 × 2 factorial design. Over the course of 12 mo, TE increased upper and lower body muscle strength by 8-14% (P = 0.015 to <0.001), fat-free mass 4.04 kg (P = 0.032), lumbar spine bone mineral density (BMD) 4.19% (P < 0.001), and total hip BMD 1.96% (P = 0.024) while reducing total body fat -3.87 kg (P < 0.001) and trunk fat -1.88 kg (P = 0.0051). In the first 3 mo, testosterone increased hematocrit 4.13% (P < 0.001). Coadministration of finasteride did not alter any of these effects. Over 12 mo, testosterone also increased prostate volume 11.4 cm(3) (P = 0.0051), an effect that was completely prevented by finasteride (P = 0.0027). We conclude that a higher-than-replacement TE combined with finasteride significantly increases muscle strength and BMD and reduces body fat without causing prostate enlargement. These results demonstrate that elevated DHT mediates testosterone-induced prostate enlargement but is not required for benefits in musculoskeletal or adipose tissue.

[1]  J. Finkelstein,et al.  Gonadal steroids and body composition, strength, and sexual function in men. , 2013, The New England journal of medicine.

[2]  Amy Shah,et al.  Androgens inhibit adipogenesis during human adipose stem cell commitment to preadipocyte formation , 2013, Steroids.

[3]  T. Travison,et al.  Risk factors associated with cardiovascular events during testosterone administration in older men with mobility limitation. , 2013, The journals of gerontology. Series A, Biological sciences and medical sciences.

[4]  M. Tillman,et al.  17β-Hydroxyestra-4,9,11-trien-3-one (Trenbolone) preserves bone mineral density in skeletally mature orchiectomized rats without prostate enlargement. , 2012, Bone.

[5]  D Andrew Loblaw,et al.  Screening for prostate cancer with prostate-specific antigen testing: American Society of Clinical Oncology Provisional Clinical Opinion. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  T. Vaisar,et al.  Testosterone replacement in hypogonadal men alters the HDL proteome but not HDL cholesterol efflux capacity[S] , 2012, Journal of Lipid Research.

[7]  S. Borst,et al.  Intracrine and myotrophic roles of 5α-reductase and androgens: a review. , 2012, Medicine and science in sports and exercise.

[8]  T. Travison,et al.  Effect of testosterone supplementation with and without a dual 5α-reductase inhibitor on fat-free mass in men with suppressed testosterone production: a randomized controlled trial. , 2012, JAMA.

[9]  A. Matsumoto,et al.  Dutasteride reduces prostate size and prostate specific antigen in older hypogonadal men with benign prostatic hyperplasia undergoing testosterone replacement therapy. , 2011, The Journal of urology.

[10]  K. Sjögren,et al.  Reduced Bone Mass and Muscle Strength in Male 5α-Reductase Type 1 Inactivated Mice , 2011, PloS one.

[11]  S. Borst,et al.  17β-Hydroxyestra-4,9,11-trien-3-one (trenbolone) exhibits tissue selective anabolic activity: effects on muscle, bone, adiposity, hemoglobin, and prostate. , 2011, American journal of physiology. Endocrinology and metabolism.

[12]  M. Seibel,et al.  Long-Term Effects of Dihydrotestosterone Treatment on Prostate Growth in Healthy, Middle-Aged Men Without Prostate Disease , 2010, Annals of Internal Medicine.

[13]  G. B. Phillips Adverse events associated with testosterone administration. , 2010, The New England journal of medicine.

[14]  J. Nelson,et al.  Inhibition of 5α‐reductase enhances testosterone‐induced expression of U19/Eaf2 tumor suppressor during the regrowth of LNCaP xenograft tumor in nude mice , 2010, The Prostate.

[15]  K. Iczkowski,et al.  Dutasteride prevents the growth response to testosterone in benign and androgen-sensitive malignant prostate cells. , 2010, International journal of clinical and experimental medicine.

[16]  Amy T. Wang,et al.  Clinical review 1: Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. , 2010, The Journal of clinical endocrinology and metabolism.

[17]  V. Montori,et al.  Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. , 2010, The Journal of clinical endocrinology and metabolism.

[18]  S. Borst,et al.  Tissue selectivity and potential clinical applications of trenbolone (17β-hydroxyestra-4,9,11-trien-3-one): A potent anabolic steroid with reduced androgenic and estrogenic activity , 2010, Steroids.

[19]  R. Kornowski,et al.  Hematocrit level as a marker of outcome in ST-segment elevation myocardial infarction. , 2010, The American journal of cardiology.

[20]  S. Bhasin,et al.  Effects of graded doses of testosterone on erythropoiesis in healthy young and older men. , 2008, The Journal of clinical endocrinology and metabolism.

[21]  C. Gregory,et al.  Anabolic effects of testosterone are preserved during inhibition of 5alpha-reductase. , 2007, American journal of physiology. Endocrinology and metabolism.

[22]  Christina Wang,et al.  The Effect of 5α-Reductase Inhibition with Dutasteride and Finasteride on Semen Parameters and Serum Hormones in Healthy Men , 2007 .

[23]  G. Ostir,et al.  Androgen Treatment and Muscle Strength in Elderly Men: A Meta‐Analysis , 2006, Journal of the American Geriatrics Society.

[24]  Claudio Cobelli,et al.  DHEA in elderly women and DHEA or testosterone in elderly men. , 2006, The New England journal of medicine.

[25]  C. Roehrborn,et al.  The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations. , 2006, The Journal of urology.

[26]  V. Montori,et al.  Testosterone use in men and its effects on bone health. A systematic review and meta-analysis of randomized placebo-controlled trials. , 2006, The Journal of clinical endocrinology and metabolism.

[27]  Martin L. Lee,et al.  Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. , 2005, The journals of gerontology. Series A, Biological sciences and medical sciences.

[28]  J. Kaufman,et al.  The decline of androgen levels in elderly men and its clinical and therapeutic implications. , 2005, Endocrine reviews.

[29]  A. Matsumoto,et al.  Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. , 2005, The Journal of clinical endocrinology and metabolism.

[30]  Shalender Bhasin,et al.  Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle. , 2005, The Journal of clinical endocrinology and metabolism.

[31]  N. Watts,et al.  Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. , 2004, The Journal of clinical endocrinology and metabolism.

[32]  Michael M Lieber,et al.  The influence of finasteride on the development of prostate cancer. , 2003, The New England journal of medicine.

[33]  E. Nieschlag,et al.  Prostate volume and growth in testosterone-substituted hypogonadal men are dependent on the CAG repeat polymorphism of the androgen receptor gene: a longitudinal pharmacogenetic study. , 2003, The Journal of clinical endocrinology and metabolism.

[34]  R. Wolfe,et al.  Testosterone administration to older men improves muscle function: molecular and physiological mechanisms. , 2002, American journal of physiology. Endocrinology and metabolism.

[35]  A. Colao,et al.  Estrogens and health in males , 2001, Molecular and Cellular Endocrinology.

[36]  R. Eastell,et al.  Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. , 2000, The Journal of clinical investigation.

[37]  S. Borson,et al.  The Mini‐Cog: a cognitive ‘vital signs’ measure for dementia screening in multi‐lingual elderly , 2000, International journal of geriatric psychiatry.

[38]  A. Iranmanesh,et al.  Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. , 2000, The Journal of clinical endocrinology and metabolism.

[39]  A. Vermeulen,et al.  A critical evaluation of simple methods for the estimation of free testosterone in serum. , 1999, The Journal of clinical endocrinology and metabolism.

[40]  J. Compston,et al.  The localization of androgen receptors in human bone. , 1997, The Journal of clinical endocrinology and metabolism.

[41]  S. B. Pedersen,et al.  Identification of steroid receptors in human adipose tissue , 1996, European journal of clinical investigation.

[42]  N. Ancy,et al.  The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. , 1996 .

[43]  M. Barry,et al.  The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. , 1992, The Journal of urology.

[44]  A. Meikle Testosterone and Growth Hormone Improve Body Composition and Muscle Performance in Older Men , 2010 .

[45]  I. Harris,et al.  A Systematic Review and Meta-Analysis of Randomized Controlled Trials , 2010 .

[46]  V. Montori,et al.  Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials. , 2007, Mayo Clinic proceedings.

[47]  Jun Hak Lee,et al.  Inhibition of 5alpha-reductase blocks prostate effects of testosterone without blocking anabolic effects. , 2005, American journal of physiology. Endocrinology and metabolism.

[48]  R. Casaburi,et al.  The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. , 1996, The New England journal of medicine.